Program Description | Description of Fellowship Program | Other Members | Publications | Awards
Program Description
The fellow will be based at Tufts Medical Center and will actively collaborate with members of the Department of Pharmacy Services and Department of Medicine, Pulmonary, Critical Care, and Sleep Division For more information on other post-doctoral educational programs in the Department of Pharmacy, at Tufts Medical Center, including the Pharmacy Practice Residency, please click here. For more information on Tufts University's Medical Library, click here.
Program Director: John W. Devlin, Pharm.D., BCPS, FCCM, Associate Professor, Bouve College of Health Sciences,School of Pharmacy, Northeastern University Clinical Pharmacist, Medical Intensive Care Unit, Tufts-New England Medical Center, Boston, MA
Contact Information:
206 Mugar Life Science Building
Northeastern University
Boston, MA 02115
Phone: 617-373-8171
Fax: 617-373-7655
Email: j.devlin@neu.edu
Description of Fellowship Program
A. Overview The critical care fellowship at Northeastern University and Tufts-New England Medical Center (T-NEMC) is a new program. The primary goal of this postdoctoral fellowship program is to provide the ICU pharmacist with the skills to be able to answer pharmacotherapy-related questions posed in every day clinical practice through the design, implementation and and evaluation of methodologically-sound studies. The fellowship program will integrate didactic training, clinical experience and active participation in the development and completion of original research in critically ill patient populations. Development of laboratory-based analytical skills and proficiency in data analysis are additional major goals of the fellowship program. Research participation will account for more than 75% of the fellow's activities.
Over the course of the two-year program, the fellow will be expected to assume responsibility for developing 2-3 research proposals for which the fellow will act as the principal investigator. Through these proposals, the fellow will gain experience at protocol development including methodological and statistical design considerations, budget preparation, the IRB submission process, grantsmanship, patient enrollment including obtainment of informed consent, chart documentation and adverse event reporting, appropriate study record keeping and data analysis. The fellow will also collaborate (co-investigator status) with the preceptor, other residents and fellows, and investigators outside the department in the design and implementation of several additional research proposals.
While independent research is the primary focus of the program, the fellow will also be exposed to multi-center Phase II, III and IV studies in terms of patient enrollment, case report documentation and IRB-related documentation. The fellow will be responsible for the preparation and submission of their research results for national presentation in the form of platform and/or poster presentation in addition to subsequent preparation and submission of a manuscript to an appropriate peer-reviewed journal for publication. The fellow will have the opportunity to didactically teach PharmD students and other health care professionals and to precept both pharmacy and PharmD students during their MICU rotation.
B. Length and Distribution of the Fellowship Activities
Duration of fellowship: 2 years
Percentage of the fellow's time spent in each activity:
Research 75%
Teaching 15%
Patient Care 10%
C. Experiences Enabling the Fellow to Become an Independent Researcher
The fellow will gain clinical research experience at T-NEMC and laboratory research experience in the laboratory of Dr. Barbara Waszczak at School of Pharmacy, Northeastern University (see below). Throughout the program, the fellow will be required to attend the weekly clinical pharmacy rounds at T-NEMC, the bi-weekly department of pulmonary/critical care research rounds, and pertinent lectures at the School of Pharmacy at Northeastern University. The fellow will also be encouraged to attend all relevant seminars and workshops offered throughout the academic year at both Northeastern University and T-NEMC including the monthly pharmacy colloquium, medical grand rounds, and visiting professor presentations.
1. Clinical Research
The fellow will gain experience developing a �bedside� pharmacotherapy-related question into a precise research hypothesis. Through interaction with the preceptor and collaboration with expert pharmacist and physician researchers, the fellow will learn how to develop a methodologically-sound, yet feasible research protocol. The fellow will learn how to identify appropriate research funding sources. An emphasis will be given to participation in the application process for competitive research grants by working with the preceptor in addition to members of the Division of Pulmonary and Critical Care Medicine at T-NEMC, the Department of Pharmacy at T-NEMC, and the Department of Pharmacy Practice at Northeastern University. The fellow will learn how to develop a study budget that incorporates institutional or university overhead costs. Fellows will gain experience in identifying appropriate grant funding agencies from discussions with the preceptor, by example (preceptor, other faculty members), and by circulation of both Northeastern and Tufts� University postings of potential grant funding agencies. The fellow will gain experience in the IRB application process (ie. drafting consent forms and completing protocol summary forms) in addition to gaining a general appreciation for the role of the IRB and the mandatory communications (e.g. adverse event reporting, protocol extensions etc) often necessary throughout the duration of the research protocol.
The fellow will develop skills to efficiently identify patients for both their own primary research projects in addition to those of the preceptor and attending pulmonologists. Experience will be gained in obtaining informed consent from both patients and next-of-kin, appropriate chart documentation, as well as overcoming the barriers that can arise during the enrollment phase. Familiarity with case report form reporting procedures will also be gained and the fellow will have the opportunity to participate in meetings with pharmaceutical study monitors, co-investigators, and research nurses. The fellow will learn to use the appropriate spreadsheet and statistical software to analyze, summarize, and interpret study results. Study results will be incorporated into an abstract and submitted for presentation to national meetings. Subsequently, the fellow will participate in the writing of a study manuscript for submission to a peer-reviewed journal.
2. Laboratory Research
The fellow will complete a two month rotation in the laboratory of Dr.Barbara Waszczak, Associate Professor of Pharmacology, School of Pharmacy, Northeastern University. Dr Waszczak's research focuses on deciphering how dopamine regulates specific neuronal populations within the motor and limbic circuits to ultimately facilitate movement and mediate the reward functions of dopamine.
A number of different experimental approaches are used to study these disorders in rat models. Fellows will have an opportunity to become involved in electrophysiological, anatomical, or behavioural research aimed at determining how disruptions of the dopamine system change the output from the circuitry. Currently, experiments involve intracerebral microinjections of drugs into the rat brain to create an animal model of Parkinson�s disease, and then using electrophysiological methods to assess how the lesions change the firing of neurons downstream from the lesion. The laboratory training will include an overview of the OSHA safety guidelines for laboratories and the Good Laboratory Practice (GLP) regulations, performance of basic laboratory techniques, and assay validation. Fellows will be given training in basic laboratory skills, such as handling and dosing rats, small animal stereotaxic surgery, preparing solutions, pipetting, weighing, carrying out research protocols, monitoring of electrophysiologic responses, recording of data, management of a data notebook, and data analysis.
3. Educational Opportunities
- Coursework The fellow is required to complete coursework offered by the Graduate Program in Public Health, School of Medicine, Tufts University and/or Department of Biostatistics, College of Arts and Sciences, Northeastern University in the areas of Research Design, Epidemiology, and Biostatistics.
- Didactic or experiential teaching The fellow will be actively involved in two Northeastern University doctor of pharmacy courses: the research design course and the cardiology/critical care module of the therapeutics course. Other opportunities to teach medical students, medical residents, and other allied health professionals are available. The fellow will have the opportunity to preceptor both T-NEMC pharmacy residents and Northeastern University doctor of pharmacy students during their MICU rotation at T-NEMC. The fellow will also be expected to act as a clinical resource to the other pharmacists at T-NEMC. The fellow will also have the opportunity to complete rotations in the SICU and CCU while at T-NEMC. The fellow will not be required to provide clinical or distributive coverage.
4. Other Professional Experience
The fellow will actively participate with the preceptor in academic reviewing for Critical Care Medicine, Pharmacotherapy, Annals of Pharmacotherapy, and ACCP and SCCM research abstracts. The fellow will be encouraged to further develop critical appraisal and writing skills by participating in the preparation of review articles, textbook chapters, and letters to the editor. The fellow may also be required to perform minor administrative functions in the Department of Pharmacy Practice at Northeastern University.
D. Facilities Available
1. Clinical Research Facilities Founded at the Boston Dispensary in 1796, T-NEMC is the oldest permanent medical facility in New England. The 474 bed medical center serves as the principal teaching hospital for Tufts University School of Medicine and is internationally renowned for its transplantation services, general surgery using both traditional and minimally invasive techniques, vascular surgery, cancer care, cardiology and cardiothoracic surgery. T-NEMC is in the top five percent of all institutions nation-wide receiving National Institute of Health Funding. The 24 pharmacists in the Department of Pharmacy offer pharmaceutical care through a wide variety of patient care programs. Staff actively participate in educational and research programs with T-NEMC, Tufts University School of Medicine, and the School of Pharmacy at Northeastern University. An active and well funded research program between the Department of Pharmacy and The Health Institute at the Medical Center is focused on the assessment of patient outcomes. Pharmacy residents have been trained in an ASHP-accredited training program for more than 25 years. In addition, the journal Pharmacotherapy is supported by and published at the Medical Center.
T-NEMC provides care to the critically ill in a 14-bed medical intensive care unit (MICU), a 10-bed surgical ICU, a 12-bed coronary ICU, and a 10-bed cardiothoracic surgery ICU. More than 800 patients are admitted each year to the MICU at T-NEMC. Members of the Pulmonary and Critical Care Division of the Department of Medicine lead a multidisciplinary approach to critical care that incorporates nursing, nutrition support, respiratory care, social work and pharmacy expertise. The MICU at T-NEMC is a part of project IMPACT, is the site for numerous research studies, and will be the major practice, teaching and research site for the fellowship program. Dr. Devlin currently provides clinical pharmacy services in the MICU and has a number of research projects either underway or in the planning stage for this population. Dr. Devlin is a member of the Pulmonary and Critical Care Division and regularly participates in research-related meetings and rounds. Members of this division will take an active role in supporting the fellowship program.
2. Laboratory Research Facilities Dr. Wasczak has a 600 sq ft laboratory that is located on the 4th floor of the Mugar Life Sciences Building at Northeastern University. Two fully equipped stations for extracellular electrophysiology are available in separated, small rooms within the main laboratory. Each set-up is equipped with: David Kopf small animal stereotaxic with 2 electrode manipulators, hydraulic microdrive, Tektronix dual beam storage oscilloscope with 2 differential amplifiers and time base, microprobe amplifier and slope height window discriminator with timed counter, Datel printer, microiontophoresis unit, Gould physiological recorder, audio monitor, VCR and recorder adapter for taping experiments, YSI-telethermometer coupled to a small animal heating pad, Fintronics bi-polar constant current source. The following equipment is shared by users of both set-ups: Narashige PE-2 microelectrode puller, electrode impedance tester, David Kopf microinjection unit for stereotaxic delivery of microliter volumes into brain, Harvard Apparatus dual infusion pump for bilateral striatal drug infusions, oscilloscope camera, WPI interval generator with 2 pulse train modules and stimulus isolator. In addition to the above, a small room adjacent to the main laboratory is equipped as a dedicated surgical space for making lesions in rats. This room houses a Kopf small animal stereotaxic with adaptors to permit bilateral angled stereotaxic surgery, a hot bead instrument sterilizer, Harvard Apparatus dual infusion pump for intracerebral drug infusions, and routine surgical supplies. Also present in the main laboratory are the following: cryostat, AO microtome with freezing stage, light microscope, dissecting microscope, pH meter, analytical balance, refrigerator and other routine laboratory equipment.
3. Medical Library The Health Sciences Library has over 50,000 books in its collection and subscribes to over 900 medical journals. Tufts University patrons have access (through the combined collections of the 3 campus libraries) to over 13,000 electronic journals of which 3684 of these are biomedical titles.
4. Computer Facilities The fellow will be provided with office space that includes an IBM-compatible Pentium desktop computer and printer and access to a Pentium laptop. This computer is online with T-NEMC�s computerized LAN system and is hardwired to T-NEMC�s internet facility. The fellow may also access T-NEMC�s mainframe computer via the internet from their office desk and will be provided with an email account. Software available to the fellow from their personal computer or form the LAN within the hospital includes: Word, Excel, Powerpoint, Access, SPSS 11.0, and Sigmaplot. There is strong information support at T-NEMC. The fellow will also be provided with a telephone having voicemail capabilities and an alpha numeric pager.
E. Program Administration and Funding
1. Recruitment Strategies for Fellowship Applicant
Dr. Devlin will be posting an advertisement for a critical care fellow at the upcoming meeting of the ASHP Midyear Meeting and listing the program in ACCP'ss Directory of Residencies and Fellowships. He will also be contacting directors of critical care residency programs in effort to inform current critical care pharmacy residents of this new fellowship program. Interested applicants will be required to submit a letter of interest, 3 letters of recommendation, and a current college transcript. A ranking of candidates will be completed by the fellowship faculty and top-ranked candidates will be interviewed. Minimum requirements for the fellowship program include a Pharm.D. and eligibility for licensure. Completion of a pharmacy practice or critical care speciality residency is desirable, although not mandatory.
2. Stipend and Benefits The fellow will receive an annual salary of $ 40, 000 per year plus full medical and dental coverage (26% of base salary). The fellow will receive two weeks of paid vacation each year. Additional benefits include: paid membership into the Society of Critical Care Medicine and paid expenses to attend professional meetings and symposiums. Funding for the fellowship program (~$50,000) per year will be primarily dependent on competitive research grants (see attached sources of funding memorandum).
3. Other Pertinent Program Information A fellowship committee made up of the preceptor and representatives from the Northeastern University School of Pharmacy and the Division of Pulmonary and Critical Care Medicine at T-NEMC will meet on a quarterly basis to evaluate progress during the fellowship.
F. Program Faculty John W. Devlin, Pharm.D., BCPS, FCCM, Associate Professor of Pharmacy, Northeastern University School of Pharmacy Clinical Pharmacist, Medical ICU, Tufts-New England Medical Center.
1. General Qualifications
Dr. Devlin will have overall responsibility for the development of the fellow's clinical research, practice and teaching skills. Dr. Devlin has worked in critical care pharmacy practice for more than 14 years and has a Bachelor of Science in Pharmacy and Doctor of Pharmacy both from the University of Toronto, a pharmacy practice residency, and a Fellowship in Critical Care Pharmacy from Henry Ford Hospital in Detroit, MI. His research and practice is based in the 14-bed medical intensive care unit at Tufts-New England Medical Center. To date he has obtained competitive research funding support for two prospective protocols (Total $137,000 funding) and has a number of protocols currently under consideration). He is actively involved in other research projects within the Division of Pulmonary/Critical Care Medicine and Pharmacy. He has been the primary preceptor for the research projects for pharmacy residents at T-NEMC. Dr. Devlin attends regular research development meetings with the other members of the Pulmonary and Critical Care Medicine Division at T-NEMC and it is anticipated that his involvement in the research activities of the division will increase substantially over time. During his 5 years at Detroit Receiving Hospital, Dr. Devlin obtained more than $100,000 of independent research funding and was able to establish a Critical Care Pharmacy Fellowship Program through the College of Pharmacy at Wayne State University. His first fellow, Dr. Sal Kanji, successfully completed this two-year program in June 2002 (Appendix 1). To date, Dr. Kanji, has presented 11 research abstracts at national/international meetings including a recent platform presentation at the 2002 European Society of Critical Care Medicine's Congress. In addition, Dr. Kanji has also published seven papers and four book chapters. Three additional research papers have been submitted for publication. In addition to training a critical care fellow, Dr. Devlin supervised the research projects of five pharmacy practice residents while in Detroit.
Dr. Devlin has been an active member of the Society of Critical Care Medicine (SCCM) since 1996. He has been a member of the CPP Section Advisory Board since 1998, most recently as the Chair of the CPP section. He has also been a member of SCCM�s Membership Committee, a Presidential Task Force on Member Communication and the ACCM/SCCM Task Force on ICU Restraints, the results of which will soon be published in Critical Care Medicine. This past year, Dr. Devlin achieved Fellowship status in the ACCM. Over the past seven years, Dr. Devlin has attended every SCCM Congress, presenting 10 research abstracts and one invited presentation. He is the recipient of an SCCM Educational Scholarship Research Award in 1998, the Nursing Section Research Award in 2000, and three Presidential Citations. Dr. Devlin remains an active reviewer for Critical Care Medicine.
2. SCCM/CPP Section Activity
Dr. Devlin has been an active member of SCCM since 1996. He has been a member of the CPP Section Advisory Board since 1998, most recently as the Chair of the CPP section. He has also been a member of SCCM�s Membership Committee, a Presidential Task Force on Member Communication and the ACCM/SCCM Task Force on ICU Restraints, the results of which will soon be published in Critical Care Medicine. This past year, Dr. Devlin achieved Fellowship status in the ACCM. Over the past seven years, Dr. Devlin has attended every SCCM Congress, presenting 10 research abstracts and one invited presentation. He is the recipient of an SCCM Educational Scholarship Research Award in 1998, the Nursing Section Research Award in 2000, and three Presidential Citations. Dr. Devlin remains an active reviewer for Critical Care Medicine.
3. Commitment to the Critical Care Discipline
Dr. Devlin has maintained an active critical care pharmacy practice since 1989 and currently attends MICU patient care rounds at T-NEMC 3-5 mornings per week. Since 1996, he has provided experiential training to more than 35 doctor of pharmacy students, 24 pharmacy residents (both general and specialized) and five pharmacy fellows. He has provided a number of didactic lectures on various critical care and research-related topics at Wayne State University and currently coordinates the cardiology/critical care therapeutics module in the Doctor of Pharmacy program at Northeastern University. Dr. Devlin has been invited to deliver more than 50 invited presentations pertaining to various critical care-related topics at local, state, national and international forums to pharmacists, physicians and nurses since 1996.
Other Members
Erik Garpestad, MD
Dr. Garpestead is an Assistant Professor of Medicine, Tufts University and Director of the MICU at T-NEMC. After a successful tenure at Beth-Isreal Deaconess Hospital, he recently relocated to T-NEMC. He is an active participant in the development of critical care-focused research projects at T-NEMC.
Nicholas Hill MD, FCCP
Dr. Hill is a Professor of Medicine, Tufts University and Chief of the Division of Pulmonary/Critical Care Medicine at T-NEMC. He is a world authority on non-invasive mechanical ventilation and has authored numerous peer-reviewed articles in this and other pulmonary/critical care-focussed areas. He was a member of the International Consensus Conference on noninvasive positive pressure ventilation in acute respiratory failure and has assumed various leadership roles within the American College of Chest Physicians.
Barbara L. Waszczak, PhD
Dr. Waszczak, is an Associate Professor of Pharmacology at Northeastern University. Her research is focused on deciphering how dopamine regulates specific neuronal populations within the motor and limbic circuits to ultimately facilitate movement and mediate the reward functions of dopamine. She will supervise the two month laboratory experience for the fellowship program.
Jack Reynolds, Pharm.D.
Dean, School of Pharmacy, Northeastern University
Edward Decker, Pharm.D.
Associate Director, Department of Pharmacy, T-NEMC Frank Massaro, Pharm.D.
Associate Director, Department of Pharmacy, T-NEMC William Gouveia, Pharm.D.
Director, Department of Pharmacy, T-NEMC
G. Fellowship Program Application Procedures
Degree Requirements: Pharm.D. and residency training or comensurate clinical experience preferred. Please send a letter of interest, Curriculum Vitae, and arrange to have three letters of reference sent to: John W. Devlin, Pharm.D., BCPS, FCCM,
241 Mugar Life Science Building
Northeastern University
Boston, MA 02115
Phone: 617-373-8171
Fax: 617-373-7655
Email: j.devlin@neu.edu
Select Presentations and Publications of the Program Director
Publications
Ahrens CL, Barletta JF, Kanji S, Tyburski JG, Wilson RF, Janisse JJ, Devlin JW. The effect of low-calorie parenteral nutrition on the incidence and severity of hyperglycemia in surgical patients : A randomized, controlled trial. Surgery 2004 (in press).
Devlin JW, Barletta JF. Reevaluating the role of albumin for fluid resuscitation: Implications of the saline versus albumin fluid evaluation (SAFE). Am J Health Syst Pharm 2004. (in press)
Nguyen CM, Barletta JF, Devlin JW. Utilization of acid suppression agents following acute, non-variceal, upper gastrointestinal bleeding. Hospital Pharmacy 2004 (in press).
Devlin JW, Welage LS. The cost effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions. Crit Care Med 2004; 32:1415-6.
Devlin JW, Seta ML, Kanji S, Somerville AL. Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann Pharmacother 2004; 38(5):755-9.
Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. PharmacoEconomics 2003; 21(18):1331-1340.
Maccioli GA, Dorman T, Brown BR, Mazuski JE, McLean BA, Kuszaj JM, Rosenbaum SH, Frankel LR, Devlin JW et al. Clinical practice guidelines for the maintenance of patient physical safety in the intensive care unit: Use of restraining therapies American College of Critical Care Medicine Task Force 2001-2002. Crit Care Med 2003;31:2665-76.
Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW. Bioavailability of gatifloxacin by nasogastric administration with and without concomitant enteral feeding in critically ill patients. Crit Care Med 2003;31:1347-1352.
Delgado G, Barletta JF, Kanji S, Tyburski JG, Wilson RF, Devlin JW. Characteristics of prophylactic antibiotic strategies following penetrating abdominal trauma at a level one urban trauma center: A comparison to the EAST Guidelines. J Trauma 2002; 53:673-8.
Kanji S, Barletta JF, Janisse J, Kruse JA, Devlin JW. Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy. Pharmacotherapy 2002; 22:823-30.
McKinnon PS, Goff DA, Kern JW, Devlin JW, Barletta JF, Sierawski SJ , Mosenthal AC, Gore P, Ambegaonkar AJ, Lubowski TJ. Temporal assessment of candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136:1401-9.
Devlin JW, Fraser GF, Kanji S, Riker R. Sedation assessment in critically ill adults. Ann Pharmacother 2001; 35:1624-32.
Kanji S, Devlin JW, Piekos K, Racine E. Recombinant human activated protein C (drotrecogin alfa activated): A novel therapy for severe sepsis. Pharmacotherapy 2001; 21:1389-402.
Tyburski JG, Dente C, Wilson RF, Steffes C, Devlin JW, Carlin A, Shanti C. Differences in arterial and mixed venous IL-6 levels: The lungs as a source of cytokine storm in sepsis. Surgery 2001:130;748-52.
Devlin JW, Tyburski JG, Moed B. Implementation and evaluation of enoxaparin deep vein thrombosis prophylaxis guidelines after major trauma. Pharmacotherapy 2001; 21:740-7.
Devlin JW, Coplin WM, Murry KR, Rengachary SS, Wilson RF. Nimodipine induced acute hypoxemia. Neurosurgery 2000; 47:1243-7.
Devlin JW. Pain assessment in seriously ill patients: Can family members play a role? Crit Care Med 2000; 28:1660-61.
Devlin JW, Boleski G, Mlynarek M, Nerenz D, Peterson E, Horst HM, Zarowitz BJ. The Motor Activity Assessment Scale: A valid and reliable sedation scale for use in adult, mechanically ventilated, surgical ICU patients. Crit Care Med 1999; 27:1271-75.
Mazur JE, Devlin JW, Peters MJ, Jankowski M, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: A randomized, double-blind trial. Crit Care Med 1999; 27:1257-61.
Devlin JW, Claire KS, Dulchavsky SA, Tyburski JG. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and incidence of major gastrointestinal bleeding. Pharmacotherapy 1999;19:452-60.
Devlin JW, Pettita A, Shepard A, Obeid FN. Cost-effectiveness of enoxaparin versus low-dose heparin as prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998; 18:1335-42.
Devlin JW, Peters M, Ulep S, T Ben-Menachem, Fogel R, Zarowitz BJ. Stress ulcer prophylaxis in medical ICU patients: Annual utilization in relation to the incidence of endoscopically-proven stress-related gastritis. Ann Pharmacother 1998; 32:869-74.
Makarechian N, Agro KA, Devlin JW, Trepanier ER, Einarson T, Koren G. Association between moderate alcohol consumption during pregnancy and spontaneous abortion, stillbirth, and premature birth: A meta-analysis. Can J Clin Pharmacol l998; 5(3):169-76.
Devlin JW, Holbrook AM, Fuller HD. The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacother 1997;31:689-95.
Devlin JW, Bayliff CD, Bellamy N. Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 1992; 45: 21-7.
Devlin JW, Kanji S. Managing thrombosis syndromes. In: Critical Care Module, Pharmacy Self Assesssment Program (PSAP). 4th ed. Zarowitz, BJ. (Ed). Kansas City, MO, American College of Clinical Pharmacy, 2002.
Devlin JW, Kanji S. Antimicrobial prophylaxis in surgery. In: Pharmacotherapy: The Pathophysiologic Basis of Disease. 5th ed. DiPiro JT, Talbert RL, Yee GC et al. (Eds). Stamford, CT, Appleton & Lange Inc. 2002.
Devlin JW. Critical appraisal of meta-analysis. In: Evaluating Drug Literature: A Statistical Approach. 1st ed. Slaughter R, Edwards D. (Eds). New York, NY, McGraw, Hill Inc. 2001
Devlin JW, Zarowitz BJ. Alterations in drug disposition in the elderly. In: Textbook of Critical Care.4th ed. Ayres SM, Grenvik A, Shoemaker W et al. (Eds). Philadelphia, PA, WB Saunders Co. 1999.
Presentations
Immunomodulating effects of commonly used ICU drugs: Lipid-based products. To be presented at the 34th Congress of the Society of Critical Care Medicine. Phoenix, AZ, January, 2005.
Redefining the role of PPIs for acid suppression in the critically ill. Presented at Critical Care Grand Rounds, Columbia-Presbyterian Hospital, New York, NY, April 2004.
New England Critical Care Pharmacy Symposium (8 faculty, > 100 attendees from 6 states, $28,000 budget) Newton, MA, April 2004 (Symposium Chair)
Intravenous proton pump inhibitors for the treatment and prevention of upper gastrointestinal bleeding: Exploring the controversies. Presented at the ASHP Clinical Midyear Meeting, New Orleans, LA, December 2003. (Symposium Chair)
Controversies in the management of upper gastrointestinal bleeding: Presented at the American College of Clinical Pharmacy's Spring Practice and Research Meeting. Palm Springs, CA, April 2003. (Symposium Chair)
Neuromuscular blockade in critically ill patients: review and update. Presented at the annual meeting of the California Society Health System Pharmacists, Sacramento, CA, October 2003.
Controversies in the management of acute, upper GI bleeding. Presented at Jackson Memorial Hospital, Miami, FL. March 2003.
Clinical trial design. Updates in therapeutics: The Pharmacotherapy Preparatory Course. Presented at the American College of Clinical Pharmacy's Spring Practice and Research Meeting. Palm Springs, CA, April 2003.
ICU sedation: Optimizing patient outcomes without compromising ability to wean from mechanical ventilation. Presented at the 3rd Mid-America Critical Care Symposium. University of Toledo, Toledo, OH, September 2002.
Critical care guideline review: Neuromuscular blockade in critically ill patients. Presented at the American College of Clinical Pharmacy's Spring Practice and Research Meeting. Savannah, GA, April 2002.
Optimizing acid suppressive therapy in acutely ill patients: When the proton pump inhibitors come marching in. Presented at the ASHP Midyear Clinical Meeting. New Orleans, LA, December 2001. (Symposium Chair)
The rationale use of drotrecogin alfa (activated) in severe sepsis: A workshop for health system pharmacists (8 faculty, 5 facilitators, 200 attendees from > 50 hospitals across U.S.). Dearborn, MI, August 2001. (Symposium Chair) Optimizing DVT prophylaxis in the critically ill. Presented at the Society of Critical Care Medicine�s 30th Educational and Scientific Symposium. San Francisco, CA, February 2001.
Optimizing DVT prophylaxis in surgical patients: Avoid rolling the dice! Presented at the ASHP Midyear Clinical Meeting: Contemporary antithrombotic therapy: Evaluating the clinical and economic outcomes. Las Vegas, NV, December 2000.
Optimizing acid suppressive therapy in acutely ill patients: The role for proton pump inhibitors. Presented at Trauma/Surgery Grand Rounds. Los Angeles County/University of Southern California Medical Center. Los Angeles, CA. August 2002.
Optimizing acid suppressive therapy in acutely ill patients: The role for proton pump inhibitors. Presented at the Medical College of Virginia. Richmond, VA. June 2002.
Optimizing acid suppressive therapy in acutely ill patients: The role for proton pump inhibitors. Presented to the Virginia Society of Hospital Pharmacists. Charlottesville, VA. June 2002.
Awards
SCCM Joseph F. Dasta Critical Pharmacy Research Grant (2004)
Fellow (FCCM) American College of Critical Care Medicine (2002)
Bayer Research Award. Fifth Annual Conference of Infectious Disease Pharmacotherapy: Making a Difference Symposium, Orlando, FL.
Nursing Section Research Award Society of Critical Care Medicine (2000)
Presidential Citation Society of Critical Care Medicine (2000. 2002. 2004)
Excellence in Research Award Detroit Medical Center (1999)
Bayer Publication Award Canadian Society of Hospital Pharmacists (1998)
Educational Scholarship Research Award Society of Critical Care Medicine (1998)
